SCHEMBL6035879

SCHEMBL6035879

CCOC(=O)CCc1cc(O)ccc1OC

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.50
CYP4A11 Q02928 2/20 0.50
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KMT2A Q03164 2/20 0.45
TTR P02766 1/20 0.44
POLB P06746 1/20 0.44
EGFR P00533 1/20 0.43
DPP4 P27487 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1549816 0.88 CYP4F2 (0.50) CYP4F2CYP4A11KDM4EALDH1A1GLA
SCHEMBL4035111 0.88 ALDH1A1 (0.53) CYP4F2CYP4A11KDM4EALDH1A1GLA
SCHEMBL14874390 0.87 CYP4F2 (0.51) CYP4F2CYP4A11KDM4EALDH1A1GAA
SCHEMBL5034496 0.86 BACE1 (0.48) KDM4EALDH1A1HSD17B10KMT2ATTR
SCHEMBL2691039 0.85 CYP4F2 (0.50) CYP4F2CYP4A11ALDH1A1GAAHPGD
SCHEMBL490458 0.85 HSD17B10 (0.55) CYP4F2CYP4A11KDM4EALDH1A1HSD17B10
SCHEMBL17722574 0.84 CYP4F2 (0.54) CYP4F2CYP4A11KDM4EALDH1A1GAA
SCHEMBL10604296 0.84 CYP4F2 (0.49) CYP4F2CYP4A11ALDH1A1GAAHPGD
SCHEMBL6350941 0.84 CYP4F2 (0.49) CYP4F2CYP4A11KDM4EALDH1A1GAA
SCHEMBL7694108 0.84 MEN1 (0.51) CYP4F2CYP4A11KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181186-B2 Aromatic ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-10 US disclosed
US-20150045378-A1 AROMATIC RING COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-02-12 US disclosed
EP-2816032-A1 AROMATIC RING COMPOUND Takeda Pharmaceutical Company Limited (JP) 2014-12-24 EP disclosed
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045378-A1 AROMATIC RING COMPOUND GPR119, GPR27, GPR4 CYP4F2 2229/4885CYP4A11 304/4885KDM4E 2012/4885
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 CYP4F2 90/4885CYP4A11 18/4885KDM4E 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.